Trial Profile
Phase I-II Trial, Open and Non-Randomized, to Assess the Role of Idelalisib in Patients With Acute Lymphoblastic Leukemia (ALL) Relapsed or Refractory to Other Treatments, and in Elderly Patients With ALL in Which it is Advised Against the use of Conventional Therapies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Sep 2021
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms REALIB; REALIB-LLA-2017
- 03 Feb 2021 Status changed from recruiting to discontinued.
- 19 May 2020 Planned primary completion date changed from 1 Jun 2020 to 7 Jul 2020.
- 27 Apr 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jun 2020.